Riprazo HCT


aliskiren / hydrochlorothiazide

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Riprazo HCT has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 20/09/2012

Authorisation details

Product details
Riprazo HCT
Agency product number
Active substance
  • aliskiren
  • hydrochlorothiazide
International non-proprietary name (INN) or common name
  • aliskiren
  • hydrochlorothiazide
Therapeutic area (MeSH)
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Novartis Europharm Ltd.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Wimblehurst Road
West Sussex
RH12 5AB
United Kingdom

Product information

30/08/2012 Riprazo HCT - EMEA/H/C/002420 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Treatment of essential hypertension in adults.

Riprazo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Rirpozo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

Assessment history

How useful was this page?

Add your rating